Novo Nordisk's new weight loss pill, Wegovy, is off to a strong start in the U. S. Analysts say it was prescribed over 18, 000 times in its first full week. This is a big deal because it shows people are interested in a pill they can take instead of a shot. The race to make the best weight loss pil
Novo Nordisk's shares got a nice boost on Friday. They went up by more than 5% after some early reports came out. These reports showed that their new obesity pill, Wegovy, is doing well in the U. S. market. The pill, which is the first of its kind for weight loss, had a good start. But experts say
Novo Nordisk has introduced a new pricing strategy for its weight-loss drugs, Ozempic and Wegovy. Starting now, people without insurance can buy the lowest doses for $199 a month for two months. After that, the price jumps to $349. This deal is available through the drugs' websites and select pharma
Novo Nordisk, a big player in Europe's pharma scene, saw its shares take a huge hit on Friday. Why? Their latest weight-loss drug, CagriSema, didn't meet expectations. The drug helped patients lose about 22. 7% of their body weight in late-stage trials, but that was barely better than Eli Lilly's ri
